N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES
The invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected, from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.
1 - 15 . (canceled)
16 . A pharmaceutical composition comprising:
a compound of claim 36 ; and
a pharmaceutically acceptable excipient.
17 . A method of treating a disease or condition selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy, comprising administering a compound of claim 36 to a subject in need thereof.
18 . The method of claim 17 , wherein the disease or condition is a cardiovascular disease.
19 . The method of claim 18 , wherein the cardiovascular disease is heart failure.
20 . The method of claim 19 , wherein the heart failure is congestive heart failure.
21 . The method of claim 19 , wherein the heart failure is acute congestive heart failure.
22 . The method of claim 19 , wherein the heart failure is acute decompensated heart failure.
23 . The method of claim 17 , wherein the disease or condition is ischemia or reperfusion injury.
24 - 33 . (canceled)
34 . A method of modulating in vivo nitroxyl levels, comprising administering a compound of claim 36 a subject in need thereof.
35 . A kit comprising:
a compound of claim 36 ; and
instructions for treating a disease or condition selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.
36 . A compound of formula (IIa)
or a pharmaceutically acceptable salt thereof wherein:
L is —SO 2 —;
Y is a heteroaryl, wherein said heteroaryl is unsubstituted or substituted with one or more substituents independently selected from W;
W is halo, —OH, —CN, —NO 2 , —COR 1 , —COOR 1 , —CONR 1 R 2 , —CH(C(O)R 1 ) 2 , or —SO 2 R 1 , wherein R 1 and R 2 are independently alkyl or aryl, or R 1 and R 2 are taken together to form a heterocycloalkyl, wherein said heterocycloalkyl is unsubstituted or substituted with one or more substituents;
R is hydrogen, alkyl, heterocycloalkyl, aryl, benzyl, alkoxy, heterocycloalkoxy, aryloxy, benzyloxy or —NR 3 R 4 , wherein said alkyl, heterocycloalkyl, aryl, benzyl, alkoxy, heterocycloalkoxy, aryloxy and benzyloxy are unsubstituted or substituted with one or more substituents; and
R 3 and R 4 are independently alkyl or aryl.
37 . The compound of claim 36 , wherein Y is unsubstituted heteroaryl.
38 . The compound of claim 36 , wherein, Y is heteroaryl substituted with one or more substituents independently selected from W.
39 . The compound of claim 36 , wherein Y is thienyl, furyl, pyrrolyl, pyridyl or benzofuranyl.
40 . The compound of claim 36 , wherein Y is thienyl, furyl, pyrrolyl, pyridyl or benzofuranyl substituted with one or more substituents independently selected from W.
41 . The compound of claim 36 , wherein W is halo.
42 . The compound of claim 36 , wherein W is chloro or bromo.
43 . The compound of claim 36 , wherein R is alkyl.